Premium
First‐in‐human report of MitraClip G4 implantation for severe degenerative mitral regurgitation
Author(s) -
Raghunathan Deepa,
GarciaSayan Enrique,
Dhoble Abhijeet,
Smalling Richard
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28777
Subject(s) - mitraclip , medicine , mitral regurgitation , food and drug administration , cardiology , reduction (mathematics) , functional mitral regurgitation , mitral valve , surgery , heart failure , medical emergency , mathematics , ejection fraction , geometry
Abstract The new MitraClip G4 device (Abbott Vascular) has been recently approved by Food and Drug Administration and is currently in limited release. A patient with a large mitral regurgitation (MR) jet but a relatively small mitral valve area (MVA) was not a surgical repair candidate nor an optimal MitraClip third‐generation device candidate. Therefore, we implanted the new G4 NTW device that resulted in significant MR reduction with a 57% reduction in MVA. To our knowledge, this is the first reported clinical use of the MitraClip G4 NTW device. We find that it may provide better results than a single NTR device and less reduction in MVA than two older generation devices. Further experience is needed to optimize patient selection for the four new G4 devices available.